Cataracts, glaucoma
Conditions
Interventions
Group 2:subconjunctival injectiointracameral injection of triamcinolone acetonide (0.5mg)
Group 1:subconjunctival injection of dexamethasone (3mg)
Group 3:subconjunctival injectiointracameral injection of triamcinolone acetonide (1.0mg)
Group 4:subconjunctival injectiointracameral injection of triamcinolone acetonide (1.5mg)
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Age
58 Years to 72 Years
Inclusion criteria
Inclusion criteria: Patients were diagnosed for APAC if they presented at least two typical symptoms (ocular or periocular pain, nausea or vomiting, blurry or halo vision); and showed acute increase in IOP to level > 40 mmHg (by Goldmann applanation tonometry) in conjunction with at least 3 of the signs (conjunctival injection, corneal epithelial edema, mid-dilated unreactive pupil, shall anterior chamber, glaucomflecken, and iris atrophy). No evidence of secondary glaucoma such as neovascular glaucoma, and uveitic glaucoma[18]. Recruited patients showed APAC that could be managed using anti-glaucomatous medications or paracentesis, and demonstrated IOP drop to level < 25 mmHg within 24 hours after treatment was administered.
Exclusion criteria
Exclusion criteria: Patients with hypermature cataract, secondary glaucoma, ocular trauma, history of infectious and noninfectious uveitis, and previous ocular surgeries were excluded. Patients with autoimmune diseases who take glucocorticoids or immunosuppressants were excluded. Patients showing posterior capsular rupture, iris bleeding and injury during surgery, and those could not be regularly followed up were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anterior chamber flare;Anterior chamber cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual acuity;introccular pressure; | — |
Countries
China
Contacts
Public ContactLiexi Jia
Chinese PLA general Hospital
Outcome results
None listed